deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT05216497

Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

Sponsor: Valenta Pharm JSC

Conditions COVID-19
Interventions Ingavirin®, 90 mg capsules Placebo
Updated 7 times since 2022 Last updated: Jul 25, 2023 Started: Oct 6, 2021 Primary completion: Jan 12, 2022 Completion: Apr 25, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on COVID-19, this trial is completed. The trial is conducted by Valenta Pharm JSC and has accumulated 7 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshotRecruiting~Mar 2022 – ~Aug 2023 · 17 months · monthly snapshotRecruiting~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Present [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

▶ Show 2 earlier versions

  1. Mar 2022 — Aug 2023 [monthly]

    Recruiting PHASE3

  2. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Valenta Pharm JSC
Data source: Valenta Pharm JSC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations